On February 2, Lyra Therapeutics (LYRA) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the company that Nasdaq has determined to delist the company’s common stock from The Nasdaq Stock Market. The company has requested a hearing before a Nasdaq Hearings Panel to appeal Nasdaq’s determination.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LYRA: